Progress of CDK4/6 Inhibitor Palbociclib in the Treatment of Cancer

Author(s): Fengquan Chen, Chunxi Liu, Jian Zhang, Wenfang Xu*, Yingjie Zhang*

Journal Name: Anti-Cancer Agents in Medicinal Chemistry
(Formerly Current Medicinal Chemistry - Anti-Cancer Agents)

Volume 18 , Issue 9 , 2018

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


The Cyclin-Dependent Kinases (CDKs) and their cyclin partners are key regulators of the cell cycle. These kinases are closely related to oncogenesis and have been proved to be attractive targets for designing novel anticancer agents. The CDK inhibitors can effectively suppress the excessive proliferation of tumor cells by inducing cell cycle arrest. In recent years, a large number of CDK inhibitors have entered pre-clinical and/or clinical trials. Among these compounds, the selective CDK4/6 inhibitor Palbociclib has been approved by FDA for breast cancer treatment. Moreover, Palbociclib demonstrated promising antitumor potential as monotherapy or combined therapy in numerous clinical trials. Herein, we provide a brief review focused on the recent progress of clinical studies about Palbociclib.

Keywords: Cyclin-Dependent Kinases (CDKs), palbociclib, monotherapy, combined therapy, anti-cancer, cell cycle arrest.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2018
Published on: 03 January, 2019
Page: [1241 - 1251]
Pages: 11
DOI: 10.2174/1871521409666170412123500
Price: $65

Article Metrics

PDF: 49